bioAffinity Technologies, Inc., a biotechnology company, is engaged in the development of non-invasive diagnostic tests and specific treatments for cancer. The company is headquartered in San Antonio, Texas.
| Revenue (TTM) | $5.66M |
| Gross Profit (TTM) | $1.87M |
| EBITDA | $-11.10M |
| Operating Margin | -267.60% |
| Return on Equity | -623.00% |
| Return on Assets | -107.10% |
| Revenue/Share (TTM) | $2.09 |
| Book Value | $0.81 |
| Price-to-Book | 1.17 |
| Price-to-Sales (TTM) | 0.70 |
| EV/Revenue | 0.459 |
| EV/EBITDA | -0.21 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -27.10% |
| Shares Outstanding | $6.28M |
| Float | $4.42M |
| % Insiders | 1.84% |
| % Institutions | 5.20% |
Volatility is currently contracting
bioAffinity and Biodesix pursue different cancer diagnostics strategies, but which oncology stock offers better long-term upside? Let's dive in.
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity and Pictor partner to advance next-generation lung inflammation diagnostics for asthma and COPD for personalized treatment.
bioAffinity Technologies, Inc. (BIAF) Discusses Innovations in Lung Cancer Screening Technologies for Veterans Transcript
bioAffinity's CyPath Lung sales momentum is gaining traction, but wider losses, funding needs and regulatory risks keep pressure on the stock.
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity Technology reports continued acceleration in commercial sales for its CyPath® Lung diagnostic with more than 200% growth year-over-year.
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity Technologies reports on preclinical findings that demonstrate siRNA therapy kills skin cancer cells while sparing healthy cells.
JERSEY CITY, N.J., June 18, 2026 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other lung diseases, closed its previously announced public offering of securities as described below for aggregate gross proceeds to the Company of $3.2 million, before deducting agent fees and other estimated expenses payable by the company.
SAN ANTONIO, Texas--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies announces closing of $3.2 million offering.
JERSEY CITY, N.J., June 17, 2026 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other lung diseases, priced a Public Offering of securities as described below for aggregate gross proceeds to the Company of $3.2 million, before deducting agent fees and other estimated expenses payable by the company.
bioAffinity Technologies, Inc. (BIAF) Discusses Noninvasive Testing and Risk Stratification for Indeterminate Lung Nodules Transcript
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on BIAF and any ticker you trade — then tracks every position and per-strategy win rate.
